<DOC>
	<DOC>NCT01217944</DOC>
	<brief_summary>This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).</brief_summary>
	<brief_title>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Myopia, Degenerative</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment due to choroidal neovascularization (CNV) secondary to PM Best corrected visual acuity (BCVA) in the study eye &gt; 24 and &lt; 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters High myopia (&gt; 6D), anteriorposterior elongation &gt; 26 mm; posterior changes compatible with the pathologic myopia Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal Patients with uncontrolled systemic or ocular diseases Blood pressure &gt; 150/90 mmHg History of panretinal, focal/grid laser photocoagulation or intraocular treatment with any antiVEGF or vPDT in the study eye Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pathologic myopia</keyword>
	<keyword>PM</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>CNV</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>verteporfin PDT</keyword>
</DOC>